Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

October 2021 | 69 pages | ID: S7532609FE3BEN
Global Markets Direct

Abstracts

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).
• The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Secondary (Hypogonadotropic) Hypogonadism - Overview
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
AbbVie Inc
Diurnal Group Plc
IASO BioMed Inc
Marius Pharmaceuticals LLC
Merck & Co Inc
Mereo Biopharma Group Plc
NHTherapeutics Inc
Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
Featured News & Press Releases
Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology
Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX
Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism
Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA
May 21, 2020: Marius Pharmaceuticals announces issuance of two key patents protecting its proprietary oral testosterone therapy
Jan 15, 2019: Mereo BioPharma: BGS-649 Phase 2b data to be Presented at ENDO 2019
Dec 17, 2018: Mereo BioPharma announces positive results from the safety extension study to the phase 2b clinical trial of BGS-649 for the treatment of hypogonadotropic hypogonadism in obese men
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by AbbVie Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by IASO BioMed Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Marius Pharmaceuticals LLC, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by NHTherapeutics Inc, 2021
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, 2021
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021